| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia
|
Aladag, Elifcan
|
|
|
21 |
3 |
p. 147-153
|
artikel
|
| 2 |
Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in a Patient with Concomitant Porphyria Cutanea Tarda
|
Mohamed, Zahra Abow
|
|
|
21 |
3 |
p. e264-e266
|
artikel
|
| 3 |
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial
|
Brown, Sarah
|
|
|
21 |
3 |
p. 154-161.e3
|
artikel
|
| 4 |
Breast Implant-associated Anaplastic Large Cell Lymphoma
|
Alotaibi, Shaikha
|
|
|
21 |
3 |
p. e272-e276
|
artikel
|
| 5 |
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
|
Thiruvengadam, Swetha Kambhampati
|
|
|
21 |
3 |
p. 139-146
|
artikel
|
| 6 |
Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis
|
Joshi, Namita
|
|
|
21 |
3 |
p. e248-e254
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
21 |
3 |
p. A4-A5
|
artikel
|
| 8 |
Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
|
Li, Xueqian
|
|
|
21 |
3 |
p. e227-e247
|
artikel
|
| 9 |
Excellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol
|
Sutiman, Natalia
|
|
|
21 |
3 |
p. e290-e300
|
artikel
|
| 10 |
2-[18F]-FDG PET/CT Role in Detecting Richter Transformation of Chronic Lymphocytic Leukemia and Predicting Overall Survival
|
Albano, Domenico
|
|
|
21 |
3 |
p. e277-e283
|
artikel
|
| 11 |
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
|
Graf, Solomon A.
|
|
|
21 |
3 |
p. 176-181
|
artikel
|
| 12 |
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL
|
Marshall, Shoko
|
|
|
21 |
3 |
p. 162-169
|
artikel
|
| 13 |
Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting
|
Vargas-Serafin, Cesar
|
|
|
21 |
3 |
p. 182-187
|
artikel
|
| 14 |
Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review
|
Uslu, Atilla
|
|
|
21 |
3 |
p. e267-e271
|
artikel
|
| 15 |
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis
|
Smith, Stephen D.
|
|
|
21 |
3 |
p. 170-175
|
artikel
|
| 16 |
Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma
|
Richter, Joshua
|
|
|
21 |
3 |
p. e284-e289
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
21 |
3 |
p. A7-A8, A10-A11
|
artikel
|
| 18 |
The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes
|
Makady, Nafie F.
|
|
|
21 |
3 |
p. e255-e263
|
artikel
|
| 19 |
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug–Based Regimens
|
Patel, Jai N.
|
|
|
21 |
3 |
p. 188-198.e2
|
artikel
|
Tijdschrift beschrijving